Canada Life’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5M Sell
47,440
-2,200
-4% -$195K 0.01% 750
2025
Q4
$4.33M Buy
49,640
+1,233
+3% +$101K 0.01% 808
2025
Q3
$3.15M Sell
48,407
-1,835
-4% -$104K ﹤0.01% 1031
2025
Q2
$2.78M Sell
50,242
-713
-1% -$34.2K ﹤0.01% 1052
2025
Q1
$2.46M Sell
50,955
-5,581
-10% -$234K ﹤0.01% 1114
2024
Q4
$2.18M Hold
56,536
﹤0.01% 1229
2024
Q3
$2.54M Buy
56,536
+51,323
+985% +$2.07M ﹤0.01% 1197
2024
Q2
$181K Sell
5,213
-3,870
-43% -$113K ﹤0.01% 1821
2024
Q1
$263K Buy
9,083
+3,870
+74% +$105K ﹤0.01% 1791
2023
Q4
$119K Hold
5,213
﹤0.01% 1911
2023
Q3
$87K Buy
5,213
+3,231
+163% +$62.7K ﹤0.01% 1994
2023
Q2
$55K Hold
1,982
﹤0.01% 1994
2023
Q1
$46K Hold
1,982
﹤0.01% 2078
2022
Q4
$22K Hold
1,982
﹤0.01% 2240
2022
Q3
$17K Hold
1,982
﹤0.01% 2286
2022
Q2
$16K Hold
1,982
﹤0.01% 2305
2022
Q1
$50K Hold
1,982
﹤0.01% 2155
2021
Q4
$68K Hold
1,982
﹤0.01% 2093
2021
Q3
$35K Hold
1,982
﹤0.01% 2325
2021
Q2
$89K Hold
1,982
﹤0.01% 2117
2021
Q1
$51K Hold
1,982
﹤0.01% 2290
2020
Q4
$40K Buy
+1,982
New +$42.7K ﹤0.01% 2360

Other funds holding PTGX

Canada Life's PTGX Position: Q1 2026 in Review

Canada Life reduced its Protagonist Therapeutics (PTGX) stake by 4.4% in Q1 2026, selling an estimated $195K and leaving 47,440 shares worth $5M. The position accounts for 0.01% of the portfolio, ranked #750.

Canada Life first reported a position in PTGX in Q4 2020 and has held it in 22 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Canada Life held 47,440 shares of Protagonist Therapeutics worth $5M as of Q1 2026.
  • Canada Life sold 2,200 Protagonist Therapeutics shares in Q1 2026, an estimated $195K.
  • Protagonist Therapeutics made up 0.01% of Canada Life's portfolio in Q1 2026, its #750 holding.
  • Canada Life first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.